REG - ValiRx PLC - Posting of Circular and Notice of General Meeting

ValiRxAnnouncement

17/01/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230117:nRSQ9758Ma&default-theme=true

RNS Number : 9758M  ValiRx PLC  17 January 2023

17 January 2023

ValiRx PLC

("ValiRx" or the "Company")

Posting of Circular and Notice of General Meeting

 

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to confirm
that, further to the announcement made on 13 January 2023, regarding the
Fundraising, a circular (the "Circular"), including the Notice of General
Meeting and a Form of Proxy was posted yesterday to shareholders.

The General Meeting will be held at the offices of DAC Beachcroft LLP, 25
Walbrook, London EC4N 8AF at 11.00 a.m. on 2 February 2023.

A copy of the Circular will shortly be available to download from the
Company's website at www.valirx.com/aim-rule-26
(http://www.valirx.com/aim-rule-26) .

Unless otherwise defined, all capitalised terms used but not defined in this
announcement shall have the meaning given to them in the Circular.

                                                                                 2023

 Announcement of the Fundraising                                                 13 January

 Latest time and date for applications under the Broker Offer (if not closed     5.00 p.m. on 16 January
 beforehand)

 Latest date of publication and posting of this document & the Form of           17 January
 Proxy

 First Admission and dealings in the Placing Shares expected to commence on AIM  8.00 a.m. on or around 19 January

 Latest time and date for receipt of proxy forms                                 11.00 a.m. on 31 January

 General Meeting                                                                 11.00 a.m. on 2 February

 Announcement of the results of the General Meeting                              2 February

 Second Admission and dealings in the Broker Offer Shares expected to commence   8.00 a.m. on or around 6 February
 on AIM

 Expected date for CREST accounts to be credited for Broker Offer Shares to be   6 February
 held in uncertificated form

 Despatch of definitive share certificates in respect of the Broker Offer        within 10 business days of Second Admission
 Shares to be held in certificated form, if applicable

The expected timetable relating to the Fundraising is set out below.

1. Each of the times and dates above are indicative only and if any of the
details contained in the timetable above should change, the revised times and
dates will be notified to Shareholders by means of an announcement through a
Regulatory Information Service.

 

2. All of the above times refer to London time unless otherwise stated.

 

3. All events listed in the above timetable related to the Second Admission
and the Broker Offer are conditional on the passing at the General Meeting of
the Fundraising Resolutions to provide the relevant authorities.

 

 

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

 ValiRx plc                                          Tel: +44 (0) 2476 796496

  Dr Suzanne Dilly, CEO                              www.valirx.com (http://www.valirx.com/)

                                                     Suzanne.Dilly@valirx.com
 Cairn Financial Advisers LLP (Nominated Adviser)    Tel: +44 (0) 20 7213 0880

  Liam Murray/Jo Turner/Ludovico Lazzaretti
 Cenkos Securities plc (Joint Broker)                Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)

 Turner Pope Investments (Joint Broker)              Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGEANFXFFPDEEA